Category: Crohn's

Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn’s disease, according to two new studies. These findings were published in today’s issue of the New England Journal of Medicine. Certolizumab pegol blocks tumor necrosis factor, an important cause of inflammation in Crohn’s disease.Crohn’s disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States.

Two pivotal Phase III clinical trials demonstrating the safety and sustained efficacy of CIMZIA? (certolizumab pegol) in moderate-to-severe Crohn’s disease (CD) were published in two articles in the July 19 issue of the New England Journal of Medicine (NEJM).

Pediatrics researchers have identified a gene variant that raises a child’s risk of Crohn’s disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract. The research reinforces previous results by German researchers, who found the same gene variant associated with the adult form of Crohn’s disease.

Researchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.A six-month programme has shown potential links with foodstuffs and Crohn’s Disease, and ulcerative colitis.The discovery could prompt an entire rethink in the medical profession across a range of conditions, from irritable bowel syndrome to migraine.

Seventeen-year-old Eliot Drieband explains what it’s like to have Crohn’s disease a type of inflammatory bowel disease in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for teens and being a peer counselor for other kids facing chronic, life-altering illnesses.

Abbott launches HUMIRA® (adalimumab) as a treatment for severe, active Crohn’s disease. Adalimumab is the first fully-human tumour necrosis factor antagonist (anti-TNF) to receive a licence for Crohn’s disease, a chronic inflammatory disease of the gastrointestinal tract that impairs the lives of up to 60,000 people in the UK1 and causes 70-80% of patients to require major surgery within their lifetime.

The European Commission (EC) has approved a new indication for Remicade® (infliximab) allowing for the treatment of severe, active Crohn’s disease (CD) in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy.

Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, involves both immune and nonimmune cells. Previous studies have established that the vasculature of the gut mucosa is an important nonimmune component of intestinal inflammation and that the protein C (PC) signaling pathway is an important checkpoint in the inflammatory process.

The molecular imaging power of PET/CT is invaluable in noninvasively monitoring Crohn’s disease - a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people, according to a study released by Belgian scientists at the 54th Annual Meeting of SNM, the world’s largest society for molecular imaging and nuclear medicine professionals.

Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA® (adalimumab) as a treatment for severe Crohn’s disease. HUMIRA is the first self-administered biologic for the treatment of Crohn’s disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease.